1. Jelliffe RW, Schumitzky A, Van Guilder M, et al. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Monit 1993; 15: 380–93
2. FDA. Guidance for industry: population pharmacokinetics. US Department of Health and Human Services; Food and Drug Administration; Centre for Drug Evaluation and Research & Centre for Biologics Evaluation and Research, 1999 Feb; CP 1 [online]. Available from URL:
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072137.pdf?utm_campaign=Google2&utm_source=fdaSearch&utm_medium=website&utm_term=Guidanceforindustrypopulationpharmacokinetics&utm_content=1
[Accessed 2011 Sep 1]
3. Ette EI, Williams PJ. Population pharmacokinetics I: background, concepts, and models. Ann Pharmacother 2004; 38: 1702–6
4. Shen D, Lu Z. Population pharmacokinetics studies with nonlinear mixed effects modeling. SAS Global Forum 2007 [online]. Available from URL:
http://www2.sas.com/proceedings/forum2007/148-2007.pdf
[Accessed 2011 Aug2]
5. Jelliffe RW. Some comments and suggestions concerning population pharmacokinetic modeling, especially of digoxin, and its relation to clinical therapy [online]. Available from URL:
http://www.lapk.org/pubsinfo/pdf/DOX_Tech_Rep_2012-1_4-2-12.pdf
[Accessed 2011 Aug 2]